Product Elements:
Indium in 111 oxyquinoline indium in-111 oxyquinoline indium in-111 oxyquinoline indium cation in-111 polysorbate 80
Indications and Usage:
Indications and usage indium in 111 oxyquinoline solution is indicated for radiolabeling autologous leukocytes. indium in 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. the degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. indium in 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. if localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure.
Read more...if localization or diagnosis by these methods fails or is ambiguous, indium in 111 oxyquinoline labeled leukocyte imaging may be appropriate.
Warnings:
Warnings the content of the vial of indium in 111 oxyquinoline solution is intended only for use in the preparation of indium in 111 oxyquinoline labeled autologous leukocytes, and is not to be administered directly. autologous leukocyte labeling is not recommended in leukopenic patients because of the small number of available leukocytes. due to radiation exposure, indium in 111 oxyquinoline labeled leukocytes could cause fetal harm when administered to pregnant women. if this radiopharmaceutical is used during pregnancy, the patient should be informed of the potential hazard to the fetus. indium in 111 oxyquinoline labeled autologous leukocytes should be used only when the benefit to be obtained exceeds the risks involved in children under eighteen years of age owing to the high radiation burden and the potential for delayed manifestation of long-term adverse effects.
General Precautions:
General strict aseptic techniques should be used to maintain sterility throughout the procedures for using this product. do not use after the expiration time and date (5 days after calibration time) stated on the label. the contents of the vial are radioactive. adequate shielding of the preparation must be maintained at all times. indium in 111 oxyquinoline solution, like other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. care should also be taken to minimize radiation exposure to the patient consistent with proper patient management. radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
Dosage and Administration:
Dosage and administration the recommended adult (70 kg) dose of indium in 111 oxyquinoline labeled autologous leukocytes is 7.4 to 18.5 mbq, 200 to 500 µci. indium in 111 oxyquinoline solution is intended for the radiolabeling of autologous leukocytes. the indium in 111 oxyquinoline labeled autologous leukocytes are administered intravenously. imaging is recommended at approximately 24 hours post injection. typically, anterior and posterior views of the chest, abdomen and pelvis should be obtained with other views as required. aseptic procedures and a shielded syringe should be employed in the withdrawal of indium in 111 oxyquinoline solution from the vial. similar procedures should be employed during the labeling procedure and the administration of the labeled leukocytes to the patient. the user should wear waterproof gloves during the entire procedure. the patient's dose should be measured by a suitable radioactivity calibration system immediately before administration. at this ti
Read more...me, the leukocyte preparation should be checked for gross clumping and red blood cell contamination.
Contraindications:
Contraindications none known.
Adverse Reactions:
Adverse reactions sensitivity reactions (urticaria) have been reported. the presence of fever may mask pyrogenic reactions from indium in 111 oxyquinoline labeled leukocytes. the possibility of delayed adverse reactions has not been studied.
Use in Pregnancy:
Pregnancy animal reproduction studies have not been conducted with indium in 111 oxyquinoline labeled leukocytes. it is also not known whether indium in 111 oxyquinoline labeled leukocytes can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. however, indium nitrate, a closely related compound, was teratogenic and embryopathic in hamsters. indium in 111 oxyquinoline labeled leukocytes should be given to a pregnant woman only if clearly needed. ideally, examinations using radiopharmaceuticals, especially those elective in nature, in women of childbearing capability should be performed during the first few (approximately ten) days following the onset of menses.
Pediatric Use:
Pediatric use safety and effectiveness in pediatric patients below age 18 have not been established (see warnings ).
Geriatric Use:
Geriatric use other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Description:
Description indium in 111 oxyquinoline (oxine) solution is a diagnostic radiopharmaceutical intended for radiolabeling autologous leukocytes. it is supplied as a sterile, non-pyrogenic, isotonic aqueous solution with a ph range of 6.5 to 7.5 [sodium hydroxide and hydrochloric acid may be used to adjust the ph]. each ml of the solution contains 37 mbq, 1 mci of indium in 111 [no carrier added, >1.85 gbq/mcg indium (>50 mci/mcg indium)] at calibration time, 50 mcg oxyquinoline, 100 mcg polysorbate 80, and 6 mg of hepes (n-2-hydroxyethyl-piperazine-n'-2-ethane sulfonic acid) buffer in 0.75% sodium chloride solution. the drug is intended to be used as a single-dose vial and contains no bacteriostatic agent. the radionuclidic impurity limit for indium 114m is not greater than 37 kbq, 1 µci of indium 114m per 37 mbq, 1 mci of indium in 111 at the time of calibration. the radionuclidic composition at expiration time is not less than 99.75% of indium in 111 and not more than 0.25% of indium in 114m/114. chemical name: indium in 111 oxyquinoline. the precise structure of the indium in 111 oxyquinoline complex is unknown at this time. the empirical formula is (c 9 h 6 no) 3 in 111.
Clinical Pharmacology:
Clinical pharmacology indium forms a saturated (1:3) complex with oxyquinoline. the complex is neutral and lipid-soluble, which enables it to penetrate the cell membrane. within the cell, indium becomes firmly attached to cytoplasmic components; the liberated oxyquinoline is released by the cell. it is thought likely that the mechanism of labeling cells with indium in 111 oxyquinoline solution involves an exchange reaction between the oxyquinoline carrier and subcellular components which chelate indium more strongly than oxyquinoline. the low stability constant of the oxyquinoline complex, estimated at approximately 10, supports this theory. following the recommended leukocyte cell labeling procedure, approximately 77% of the added indium in 111 oxyquinoline is incorporated in the resulting cell pellet (which represents approximately 3 to 4 Ã 10 8 wbc). cell clumping can occur and was found in about one fifth of the leukocyte preparations examined. the presence of red blood cells or
Read more... plasma will lead to reduced leukocyte labeling efficiency. transferrin in plasma competes for indium in 111 oxyquinoline. after injection of labeled leukocytes into normal volunteers, about 30% of the dose is taken up by spleen and 30% by liver, reaching a plateau at 2 to 48 hours after injection. no significant clearance of radioactivity is observed at 72 hours in these two organs. pulmonary uptake is 4 to 7.5% at 10 minutes but is lost rapidly; pulmonary radioactivity is usually visible in scans only up to about 4 hours after injection. the human biodistribution studies in three normal subjects injected with indium in 111 oxyquinoline labeled leukocytes indicate a biexponential disappearance of indium in 111 from the blood when monitored for up to 72 hours. between 9.5 to 24.4% of the injected dose remains in whole blood and clears with a biological half-time of 2.8 to 5.5 hours. the remainder (13 to 18%) clears from blood with a biological half-time of 64 to 116 hours. elimination from the body of injected indium in 111 oxyquinoline is probably mainly through decay to stable cadmium since only a negligible amount (less than 1%) of the dose is excreted in feces and urine in 24 hours. clearance from whole blood and biological distribution can vary considerably with the individual recipient, the condition of the injected cells and labeling techniques used. release of radioactivity from the labeled cells is about 3% at 1 hour and 24% at 24 hours. clearance from liver and spleen, for the purpose of calculating the radiation dose, is assumed to be equal to the physical half-life of indium in 111 (67.9 hours).
Carcinogenesis and Mutagenesis and Impairment of Fertility:
Carcinogenesis, mutagenesis, impairment of fertility although earlier studies suggested that oxyquinoline (oxine) might have carcinogenic potential, recent studies have found no evidence of carcinogenicity in either rats or mice given oxyquinoline in feed at concentrations of 1,500 or 3,000 ppm for 103 weeks. it has been reported [ten berge, r.j.m., natarajan, a.t., hardeman, m.r., et al, labeling with indium in 111 has detrimental effects on human lymphocytes, journal of nuclear medicine, 24 , 615-620 (1983)] that human lymphocytes labeled with recommended concentrations of indium in 111 oxyquinoline showed chromosome aberrations consisting of gaps, breaks and exchanges that appear to be radiation induced. at 555 kbq/10 7 , 15 µci/10 7 lymphocytes 93% of the cells were reported to be abnormal. the oncogenic potential of such lymphocytes has not been studied. it has been reported that the radiation dose to 10 8 leukocytes is 9 à 10 4 mgy (0.9 à 10 4 rads) from 18.5 mbq, 500 Â
Read more...µci [goodwin, david a., cell labeling with oxine chelates of radioactive metal ions: techniques and clinical implications, journal of nuclear medicine, 19 , 557-559 (1978)]. studies have not been performed to evaluate whether indium in 111 oxyquinoline affects fertility in male or female laboratory animals or humans.
How Supplied:
How supplied indium in 111 oxyquinoline solution is supplied in a 1 ml single-dose vial containing 37 mbq, 1 mci per ml aqueous solution at the calibration date stated on the label. vials are packaged in individual lead shields. ndc 17156-021-01 the contents of the vial are radioactive and adequate shielding and handling precautions must be maintained. this preparation is approved for use by persons licensed by the illinois emergency management agency pursuant to 32 il. adm. code section 330.260(a) and 335.4010 or equivalent licenses of the nuclear regulatory commission or an agreement state.
Package Label Principal Display Panel:
Principal display panel - 1 ml vial label indium in 111 oxyquinoline solution for the radiolabeling of autologous leukocytes. each ml contains less than 0.1 mcg indium, 50 mcg 8-hydroxyquinoline, around 100 mcg polysorbate 80, 6 mg (n-2-hydroxyethylpiperazine- n-2 ethane sulfonic acid). hepes buffer and 0.75% sodium chloride injection. ph adjusted with sodium hydroxide and hydrochloric acid. refer to prescribing information for further details. single-dose vial. discard unused portion. rx only mfd. by ge healthcare, medi-physics, inc. arlington heights, il 60004 u.s.a. in15pa lot xxxx exp dd mmm yyyy 37 mbq (1 mci) volume: 1 ml 37 mbq (1 mci) per ml at 0600 hrs cst on: dd mmm yyyy 41-8021b caution radioactive material principal display panel - 1 ml vial label